Guacetisal

Guacetisal

SCHEMBL948974

COc1ccccc1OC(=O)c1ccccc1OC(C)=O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.73
HSD17B10 Q99714 3/20 0.73
LMNA P02545 1/20 0.73
CYP1A2 P05177 1/20 0.73
CYP2C9 P11712 1/20 0.73
HPGD P15428 5/20 0.61
PTGS2 P35354 4/20 0.61
ALDH1A1 P00352 3/20 0.61
ESR1 P03372 2/20 0.61
ITGB3 P05106 1/20 0.61
ITGA2B P08514 1/20 0.61
HMGB1 P09429 1/20 0.61
TSHR P16473 1/20 0.61
GGT1 P19440 1/20 0.61
PTGS1 P23219 1/20 0.61
BLM P54132 1/20 0.61
NAPRT Q6XQN6 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
KMT2A Q03164 4/20 0.57
ESR2 Q92731 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guacetisal SCHEMBL29368893 1.00 KDM4E (0.73) KDM4EHSD17B10LMNACYP1A2CYP2C9
SCHEMBL31321657 0.89 ESR1 (0.66) KDM4EHSD17B10LMNACYP1A2CYP2C9
SCHEMBL29655351 0.87 CA12 (0.59) KDM4EHSD17B10LMNACYP1A2CYP2C9
SCHEMBL236191 0.87 CA12 (0.59) KDM4EHSD17B10LMNACYP1A2CYP2C9
SCHEMBL11521148 0.86 KDM4E (0.73) KDM4EHSD17B10LMNACYP1A2CYP2C9
SCHEMBL16193386 0.84 PTGS2 (0.57) KDM4EHSD17B10LMNACYP1A2CYP2C9
Diplosalsalate SCHEMBL30590970 0.84 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9
SCHEMBL2473332 0.84 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9
SCHEMBL20323265 0.84 KMT2A (0.68) KDM4EHSD17B10LMNACYP1A2CYP2C9
Diplosalsalate SCHEMBL25398 0.84 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255781-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-08-14 US claimed
US-12296043-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2025-05-13 US claimed
EP-4510999-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS Bristol-Myers Squibb Company (US) 2025-02-26 EP claimed
US-20240165020-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-05-23 US claimed
EP-4360653-A2 LIQUISOFT CAPSULES Patheon Softgels Inc. (US) 2024-05-01 EP claimed
US-11872307-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2024-01-16 US claimed
EP-3682872-B1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-01-03 EP claimed
WO-2023205619-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-10-26 WO claimed
US-20220211616-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2022-07-07 US claimed
US-20210046009-A1 PROTECTING ORAL OVERDOSE WITH ABUSE DETERRENT IMMEDIATE RELEASE FORMULATIONS Grünenthal GmbH (DE) 2021-02-18 US claimed
CN-103102271-A Industrialized preparation method of guacetisal and medical application of dry suspension DALIAN MINGSEN PHARMACEUTICAL CO LTD 2013-05-15 CN claimed
WO-2013020527-A1 UTILIZATION OF ALAPTIDE AS TRANSDERMAL PENETRATION MODIFIER IN PHARMACEUTICAL COMPOSITIONS FOR HUMAN AND VETERINARY APPLICATIONS CONTAINING ANTI-INFLAMMATORY DRUGS AND/OR ANTIMICROBIAL CHEMOTHERAPEUTICS UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES BRNO FACULTY OF PHARMACY (CZ) 2013-02-14 WO claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-100484515-C Guacetisal dry-mixing suspending agents and method of preparing the same SHANDONG LUOXIN PHARMACY STOCK (CN) 2009-05-06 CN claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
CN-101254172-A Guacetisal dry-mixing suspending agents and method of preparing the same SHANDONG LUOXIN PHARMACEUTICAL (CN) 2008-09-03 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
CN-1593429-A Novel oral guacetisal solid preparation and its preparing method LI JIE (CN) 2005-03-16 CN claimed